Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer
Go back to Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer| AGENUS (NASDAQ: AGEN) | Delayed: 3.04 +0.04 (1.33%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.00 | 52 Week High | $7.49 | |||
| Open | $2.99 | 52 Week Low | $2.61 | |||
| Day High | $3.10 | P/E | N/A | |||
| Day Low | $2.98 | EPS | $-1.10 | |||
| Volume | 476,060 | |||||
